Ceras Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.75 M
- Company Age 22 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
- Revenue Growth 18.65%
- Profit Growth 38.16%
- Ebitda 36.82%
- Net Worth 7.44%
- Total Assets 0.11%
About Ceras Pharmaceuticals
Ceras Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 April 2002 and has a history of 22 years and nine months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M.
The company currently has active open charges totaling ₹0.50 M.
Mahadevan Jayachanthrran and Archana Sudarshan serve as directors at the Company.
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TN2002PTC048824
- Company No.
048824
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Ceras Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahadevan Jayachanthrran  | Whole-Time Director | 24-Apr-2002 | Current |
| Archana Sudarshan | Director | 14-Sep-2014 | Current |
Financial Performance of Ceras Pharmaceuticals.
Ceras Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.65% increase. The company also saw a substantial improvement in profitability, with a 38.16% increase in profit. The company's net worth moved up by a moderate rise of 7.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ceras Pharmaceuticals?
In 2023, Ceras Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Aug 2015 | Indian Overseas Bank | ₹0.50 M | Open |
How Many Employees Work at Ceras Pharmaceuticals?
Ceras Pharmaceuticals has a workforce of 9 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ceras Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ceras Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
